Literature DB >> 17589298

A comparative analysis of serum and serum-free media for generation of clinical grade DCs.

Chiara Napoletano1, Dora Pinto, Filippo Bellati, Federica Taurino, Hassan Rahimi, Federica Tomao, Pierluigi Benedetti Panici, Aurelia Rughetti, Luigi Frati, Marianna Nuti.   

Abstract

Dendritic cells (DCs) are the most potent antigen presenting cells and are therefore widely used in cancer immunotherapy. An optimal method for the generation of DCs for clinical use remains to be established. The aim of the study was to find a serum-free media (SFM) able to generate reproducible and functional cultures of DCs for clinical studies. We characterized immature and mature DCs cultured in SFM, CellGro DC and X-VIVO15, and serum media (SM), RPMI 1640+5% human serum or autologous serum. The expression of HLA-DR, CD86, CD83 was higher in SM-cultured DCs (SM-DCs) than SFM-derived DCs (SFM-DCs). Between SFM-DCs, CellGro-cultured DCs (CellGro-DCs) showed a higher expression and an improved up-regulation capacity of all molecules as compared with X-VIVO15-derived DCs (X-VIVO15-DCs). CellGro-DCs and SM-DCs showed a similar mannose receptor expression and related endocytic capacity tested by fluorescein isothiocyanate-dextran uptake. In contrast X-VIVO15-DCs expressed low levels of mannose receptor and were unable to endocyte fluorescein isothiocyanate-dextran. DCs cultured in all conditions stimulated a mix lymphocyte reaction, but CellGro-DCs and SM-DCs induced a more potent T-cell proliferation compared with X-VIVO15-DCs. Cytokine analysis showed that after maturation, all DC cultures produced IL-12p70 and IL-10 except for X-VIVO15-DCs which only produced the latter cytokine. SM-DCs and SFM-DCs induced a TH1 polarization in allogeneic naive T cells. In conclusion, a comparative analysis of DC performance generated in different conditions allows us to determine CellGro DC as the optimal medium for the generation of clinical grade DCs.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17589298     DOI: 10.1097/CJI.0b013e318046f396

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  15 in total

1.  Optimal stimulation for CD70 induction on human monocyte-derived dendritic cells and the importance of CD70 in naive CD4(+) T-cell differentiation.

Authors:  Kazue Arimoto-Miyamoto; Norimitsu Kadowaki; Toshio Kitawaki; Satoshi Iwata; Chikao Morimoto; Takashi Uchiyama
Journal:  Immunology       Date:  2010-02-26       Impact factor: 7.397

2.  In vitro generation of cytotoxic T lymphocyte response using dendritic cell immunotherapy in osteosarcoma.

Authors:  Ye-Teng He; Qing-Min Zhang; Quan-Chun Kou; Bo Tang
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

3.  Generation of functionally mature dendritic cells from elutriated monocytes using polyinosinic : polycytidylic acid and soluble CD40 ligand for clinical application.

Authors:  S Kim; H O Kim; H J Kim; K Lee; H-S Kim
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

4.  Immune effects of trastuzumab.

Authors:  Marianna Nuti; Filippo Bellati; Valeria Visconti; Chiara Napoletano; Lavinia Domenici; Jlenia Caccetta; Ilaria Grazia Zizzari; Ilary Ruscito; Hassan Rahimi; Pierluigi Benedetti-Panici; Aurelia Rughetti
Journal:  J Cancer       Date:  2011-05-25       Impact factor: 4.207

5.  Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis.

Authors:  Rachel A Harry; Amy E Anderson; John D Isaacs; Catharien M U Hilkens
Journal:  Ann Rheum Dis       Date:  2010-06-15       Impact factor: 19.103

6.  Comparative study of clinical grade human tolerogenic dendritic cells.

Authors:  M Naranjo-Gómez; D Raïch-Regué; C Oñate; L Grau-López; C Ramo-Tello; R Pujol-Borrell; E Martínez-Cáceres; Francesc E Borràs
Journal:  J Transl Med       Date:  2011-06-09       Impact factor: 5.531

7.  HER2-based recombinant immunogen to target DCs through FcγRs for cancer immunotherapy.

Authors:  Ilaria Grazia Zizzari; Filippo Veglia; Federica Taurino; Hassan Rahimi; Elena Quaglino; Francesca Belleudi; Federica Riccardo; Morena Antonilli; Chiara Napoletano; Filippo Bellati; Pierluigi Benedetti-Panici; Maria Rosaria Torrisi; Luigi Frati; Marianna Nuti; Aurelia Rughetti
Journal:  J Mol Med (Berl)       Date:  2011-08-16       Impact factor: 4.599

8.  Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:  Sylvia Janetzki; L Price; C M Britten; S H van der Burg; J Caterini; J R Currier; G Ferrari; C Gouttefangeas; P Hayes; E Kaempgen; V Lennerz; K Nihlmark; V Souza; A Hoos
Journal:  Cancer Immunol Immunother       Date:  2009-11-06       Impact factor: 6.968

9.  Gram-negative enterobacteria induce tolerogenic maturation in dexamethasone conditioned dendritic cells.

Authors:  Raquel Cabezón; Elena Ricart; Carolina España; Julián Panés; Daniel Benitez-Ribas
Journal:  PLoS One       Date:  2012-12-27       Impact factor: 3.240

Review 10.  Optimizing dendritic cell-based immunotherapy: tackling the complexity of different arms of the immune system.

Authors:  Ilse Van Brussel; Zwi N Berneman; Nathalie Cools
Journal:  Mediators Inflamm       Date:  2012-07-18       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.